IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.830
NA - Nord America 1.576
EU - Europa 704
SA - Sud America 444
AF - Africa 48
OC - Oceania 25
Totale 11.627
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 6.885
US - Stati Uniti d'America 1.498
CN - Cina 896
HK - Hong Kong 676
BR - Brasile 331
VN - Vietnam 194
GB - Regno Unito 192
IT - Italia 169
DE - Germania 112
IN - India 53
CA - Canada 46
FI - Finlandia 42
AR - Argentina 41
NL - Olanda 35
CZ - Repubblica Ceca 28
EC - Ecuador 26
ID - Indonesia 26
AU - Australia 24
MX - Messico 24
PL - Polonia 23
TR - Turchia 23
ZA - Sudafrica 22
FR - Francia 21
UA - Ucraina 18
JP - Giappone 17
ES - Italia 16
BD - Bangladesh 14
PY - Paraguay 13
CL - Cile 9
RU - Federazione Russa 9
CO - Colombia 8
SE - Svezia 8
CH - Svizzera 5
MA - Marocco 5
PE - Perù 5
VE - Venezuela 5
ET - Etiopia 4
SA - Arabia Saudita 4
UY - Uruguay 4
AT - Austria 3
BE - Belgio 3
BY - Bielorussia 3
DZ - Algeria 3
EG - Egitto 3
IQ - Iraq 3
IR - Iran 3
KZ - Kazakistan 3
LB - Libano 3
LU - Lussemburgo 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
IL - Israele 2
IS - Islanda 2
JM - Giamaica 2
KR - Corea 2
LT - Lituania 2
MY - Malesia 2
PA - Panama 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TL - Timor Orientale 2
UZ - Uzbekistan 2
AM - Armenia 1
AO - Angola 1
BG - Bulgaria 1
BJ - Benin 1
BW - Botswana 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GH - Ghana 1
GN - Guinea 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
IE - Irlanda 1
JO - Giordania 1
KE - Kenya 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
ME - Montenegro 1
ML - Mali 1
MU - Mauritius 1
NP - Nepal 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TN - Tunisia 1
Totale 11.627
Salva come PNG Salva come JPEG
Città #
Hong Kong 667
Singapore 579
Hefei 391
Ashburn 328
Boardman 216
Dallas 178
Beijing 175
London 155
Shanghai 134
Rome 72
Ho Chi Minh City 67
Munich 62
Los Angeles 61
Council Bluffs 58
San Francisco 46
São Paulo 39
Hanoi 36
Seattle 31
Brno 28
Santa Clara 27
Turku 27
New York 26
Pune 26
West Jordan 22
Warsaw 21
Amsterdam 20
Guangzhou 20
Toronto 19
Washington 17
Mexico City 16
Rio de Janeiro 16
Tokyo 16
Helsinki 15
Montreal 15
Boston 14
Canberra 12
Da Nang 12
Guayaquil 12
Sona 11
Johannesburg 10
Chennai 9
Haiphong 9
Brasília 8
Brooklyn 8
Stockholm 8
Atlanta 7
Chicago 7
Hải Dương 7
Manchester 7
Melbourne 7
Paris 7
Shenzhen 7
Charlotte 6
Redmond 6
Thái Bình 6
Biên Hòa 5
Curitiba 5
Milan 5
Quito 5
Secaucus 5
Sydney 5
Zhengzhou 5
Ankara 4
Belo Horizonte 4
Buenos Aires 4
Can Tho 4
Central 4
Frankfurt am Main 4
Kyiv 4
Lima 4
Montes Claros 4
Naples 4
Oklahoma City 4
Phoenix 4
Shijiazhuang 4
The Dalles 4
Thái Nguyên 4
Addis Ababa 3
Asunción 3
Bari 3
Belém 3
Bologna 3
Boydton 3
Brownsville 3
Buffalo 3
Bắc Giang 3
Cachoeirinha 3
Camden 3
Campinas 3
Carapicuíba 3
Delhi 3
Florianópolis 3
Guarulhos 3
Haikou 3
Houston 3
Jackson 3
Jakarta 3
Montevideo 3
Poplar 3
Porto Alegre 3
Totale 3.970
Salva come PNG Salva come JPEG
Nome #
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 224
Advances in management of periprosthetic joint infections: an historical prospective study 209
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 206
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 205
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 202
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 200
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 199
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 197
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 195
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 191
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 191
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 191
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 190
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 189
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 189
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 189
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 188
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 187
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 182
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 180
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 180
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 180
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 179
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 178
Assessment of liver function by the exhaled breath-print during chronic liver disease 177
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 135
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 111
GH-resistance in different stages of chronic liver disease 109
Diabetes in chronic liver disease: from old concepts to new evidence 104
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 102
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 99
[A 73-year-old woman with vomiting and metabolic alkalosis] 99
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 98
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 95
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 94
A challenging alfa-fetoprotein in a cirrhotic patient 92
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 91
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 90
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 88
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 88
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 88
[A 61-year-old woman with abdominal pain and urination disorders] 87
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 87
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 83
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 82
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 82
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 81
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 80
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 80
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 80
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 78
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 74
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 73
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 71
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 69
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 67
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 65
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 64
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 64
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 58
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 50
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 49
Pain and Frailty in Hospitalized Older Adults 48
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 47
Reelin expression in human liver of patients with chronic hepatitis C infection 46
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 46
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 46
Identification of matrix metalloprotease 10 (mmp10) as a key new mediator of the regenerative response of the liver 45
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 43
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 43
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease 42
Reply to the Letter: “Low levels of transaminase and mortality risk in older people with special reference to sarcopenia” 41
Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients 40
TNF-alpha and growth hormone resistance in patients with chronic liver disease 39
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice 39
Identification of Fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure 39
What changed in the Italian internal medicine and geriatric wards during the lockdown 39
Hepatic matrix metalloproteinase-10 exerts a hepatoprotective role after acute liver inury 38
Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis 38
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development 37
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 37
Portal and interface chronic inflammation are associated with the progenitor cell compartment activation during NAFLD 37
Matrix metalloproteinase-10 contributes to hepatocellular carcinoma development in a novel crosstalk with stromal derived growth factor 1/C-X-C chemokine receptor 4 axis 36
Interplay between SIRT-3, metabolism and its tumor suppressor role in hepatocellular carcinoma 36
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 36
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 35
The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection 35
Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma 35
MMP10 EXPRESSION PROTECTS FROM ACUTE LIVER INJURY BUT CONTRIBUTES TO HEPATOCELLULAR CARCINOMA PROGRESSION 35
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 35
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 34
Multimorbidity and polypharmacy in the elderly: lessons from REPOSI 34
Hepatic matrix metalloproteinase-10 exerts a hepatoprotective role after acute liver injury 34
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen 34
Liver vitamin D receptor, CYP2R1 and CYP27A1 expression related to progression of metabolic and viral liver damage 34
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease 33
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 33
Reelin expression in liver and pancreas and its correlation with liver fibrosis 33
The hepatic expression of GH/IGF1 axis components is impaired with fibrosis progression in patients with HCV-related chronic hepatitis 33
Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis 33
Totale 9.353
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.871
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.871
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022336 0 2 8 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20262.239 620 332 457 810 20 0 0 0 0 0 0 0
Totale 11.704